Ipatasertib
Estrogen-Receptor Positive Breast Cancer
Explore 74 assets in Estrogen-Receptor Positive Breast Cancer →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Royal Marsden NHS Foundation Trust
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04920708CT.gov Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression | — | Active Not Recruiting | — | — | — |
NCT04802759CT.gov A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | — | Recruiting | — | — | — |
NCT03395899CT.gov Pre-operative Immunotherapy Combination Strategies in Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Estrogen-Receptor Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipatasertib (this asset) | Royal Marsden NHS Foundation Trust | P2 | BB · 64 |
| Exemestane | National Cancer Institute (NCI) | P4 | BBB |
| Everolimus | UNC Lineberger Comprehensive Cancer Center | P4 | BBB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Palbociclib | Forward Pharmaceuticals Co., Ltd. | P3 | BB |
| Giredestrant | Hoffmann-La Roche | P3 | BB |
| Capivasertib | Imperial College London | P2 | BB |
| Abemaciclib | Jonsson Comprehensive Cancer Center | P3 | BB |
| Ribociclib | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Estrogen-Receptor Positive Breast Cancer cohort
Other indications for Ipatasertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Prostate Carcinoma | — | P3 | B · 60 |
| Breast Cancer | — | P3 | B · 60 |
| Triple-Negative Breast Carcinoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipatasertib in Estrogen-Receptor Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipatasertib-estrogen-receptor-positive-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →